<DOC>
	<DOCNO>NCT01845779</DOCNO>
	<brief_summary>Complete response rare event metastatic anal cancer case unresectable recurrence radiochemotherapy . In University Hospital Center Besançon , 8 patient metastatic anal cancer treat 2005 2008 6 cycle chemotherapy include taxane : DCF ( Docetaxel , Cisplatin 5-Fluorouracil . In 90 % case , anal cancer related Human Papilloma Virus ( HPV ) infection , case patient HPV16 ( human papillomavirus type 16 ) genotype identify within tumor sample . The hypothesis anti-HPV response immune could generate chemotherapy DCF contribute elimination tumour cell increase complete response . The aim study analyze immune response HPV patient complete response .</brief_summary>
	<brief_title>Evaluation Immune Response Against Human Papillomavirus ( HPV ) Patients With Metastatic Cancer Anal Canal</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>ECOG performance status ≤ 1 patient metastatic anal cancer HPV+ presence measurable target lesion accord radiological criterion ( Recist V1.1 ) patient 12 month complete remission metastatic anal cancer accord radiological criterion ( Recist V1.1 ) treatment DCF regimen ( Docetaxel , Cisplatin 5Fluorouracil ) pregnancy lactation patient medical psychiatric condition disease would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>